Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

$156 Billion
Q2 2025

A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 2,671,265 shares of NTLA stock, worth $30.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,671,265

Previous 2,825,361 5.45%

Holding current value

$30.9 Million

Previous $20.1 Million 24.73%

% of portfolio

0.02%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 31, 2025	SELL	$6.28 - $9.67 $967,722 - $1.49 Million	-154,096 Reduced 5.45%	2,671,265 $25.1 Million
Q1 2025 Apr 25, 2025	SELL	$7.11 - $12.8 $1.19 Million - $2.14 Million	-167,302 Reduced 5.59%	2,825,361 $20.1 Million
Q4 2024 Jan 28, 2025	SELL	$11.41 - $21.09 $1.79 Million - $3.31 Million	-156,736 Reduced 4.98%	2,992,663 $34.9 Million
Q3 2024 Nov 05, 2024	SELL	$19.72 - $27.36 $2.14 Million - $2.96 Million	-108,290 Reduced 3.32%	3,149,399 $64.7 Million
Q2 2024 Jul 19, 2024	SELL	$20.02 - $27.22 $2.84 Million - $3.86 Million	-141,629 Reduced 4.17%	3,257,689 $72.9 Million
Q1 2024 Apr 19, 2024	SELL	$23.82 - $32.8 $1.89 Million - $2.6 Million	-79,244 Reduced 2.28%	3,399,318 $93.5 Million
Q4 2023 Jan 30, 2024	SELL	$23.16 - $32.34 $966,536 - $1.35 Million	-41,733 Reduced 1.19%	3,478,562 $106 Million
Q3 2023 Oct 30, 2023	BUY	$31.62 - $45.78 $3.97 Million - $5.75 Million	125,639 Added 3.7%	3,520,295 $111 Million
Q2 2023 Jul 31, 2023	BUY	$34.58 - $46.03 $9.74 Million - $13 Million	281,692 Added 9.05%	3,394,656 $138 Million
Q1 2023 Apr 27, 2023	BUY	$33.3 - $44.82 $4.56 Million - $6.14 Million	136,962 Added 4.6%	3,112,964 $116 Million
Q4 2022 Jan 30, 2023	BUY	$33.21 - $62.69 $400,977 - $756,919	12,074 Added 0.41%	2,976,002 $104 Million
Q3 2022 Oct 21, 2022	BUY	$53.92 - $71.7 $9.86 Million - $13.1 Million	182,792 Added 6.57%	2,963,928 $166 Million
Q2 2022 Jul 26, 2022	SELL	$38.49 - $76.21 $3.51 Million - $6.95 Million	-91,133 Reduced 3.17%	2,781,136 $144 Million
Q1 2022 Apr 27, 2022	BUY	$58.27 - $118.99 $6.9 Million - $14.1 Million	118,366 Added 4.3%	2,872,269 $209 Million
Q4 2021 Feb 02, 2022	BUY	$100.76 - $138.36 $35.7 Million - $49 Million	353,970 Added 14.75%	2,753,903 $326 Million
Q3 2021 Oct 25, 2021	SELL	$132.37 - $176.78 $96.3 Million - $129 Million	-727,670 Reduced 23.27%	2,399,933 $322 Million
Q2 2021 Aug 02, 2021	SELL	$60.88 - $161.91 $102 Million - $272 Million	-1,679,691 Reduced 34.94%	3,127,603 $506 Million
Q1 2021 Apr 30, 2021	SELL	$46.59 - $83.68 $13.8 Million - $24.9 Million	-297,068 Reduced 5.82%	4,807,294 $386 Million
Q4 2020 Feb 05, 2021	SELL	$18.83 - $63.53 $18 Million - $60.9 Million	-958,154 Reduced 15.8%	5,104,362 $278 Million
Q3 2020 Oct 30, 2020	SELL	$17.47 - $24.93 $2.32 Million - $3.31 Million	-132,673 Reduced 2.14%	6,062,516 $121 Million
Q2 2020 Jul 27, 2020	SELL	$11.14 - $22.87 $9.98 Million - $20.5 Million	-896,074 Reduced 12.64%	6,195,189 $130 Million
Q1 2020 Apr 27, 2020	SELL	$9.44 - $15.58 $823,706 - $1.36 Million	-87,257 Reduced 1.22%	7,091,263 $86.7 Million
Q4 2019 Jan 31, 2020	SELL	$10.43 - $17.67 $638,493 - $1.08 Million	-61,217 Reduced 0.85%	7,178,520 $105 Million
Q3 2019 Oct 31, 2019	BUY	$13.07 - $18.51 $65.7 Million - $93 Million	5,023,077 Added 226.61%	7,239,737 $96.7 Million
Q2 2019 Jul 29, 2019	BUY	$13.88 - $18.41 $16.2 Million - $21.5 Million	1,169,968 Added 111.78%	2,216,660 $36.3 Million
Q1 2019 May 08, 2019	BUY	$12.79 - $17.62 $13.4 Million - $18.4 Million	1,046,692 New	1,046,692 $17.9 Million

Others Institutions Holding NTLA

# of Institutions

333

Shares Held

97.2M

Call Options Held

1.66M

Put Options Held

1.03M

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $879M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.

Account

Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History